119-hconres35

HCONRES
✓ Complete Data

Exposing Congressional Drug Abuse Act

1 0
Login to track bills
Introduced:
Jun 5, 2025
Policy Area:
Congress

Bill Statistics

3
Actions
0
Cosponsors
0
Summaries
1
Subjects
1
Text Versions
Yes
Full Text

AI Summary

Generated 3 weeks ago

Here's a comprehensive analysis of the Exposing Congressional Drug Abuse Act:

Executive Summary

This concurrent resolution would establish mandatory random drug testing for all members of Congress (House and Senate). Each member would be required to undergo one random drug test per term, with positive results reported to ethics committees and members required to reimburse the cost of their tests.

Key Provisions

  • Establishes mandatory random drug testing program for all Congressional members
  • One random drug test per term for each member
  • Two-step verification process for positive results
    • Initial positive test followed by confirmation test using different chemical process
    • Medical review officer certification required
  • Results reporting structure:
    • Individual member notification
    • Relevant ethics committee notification (House or Senate)
  • Public disclosure requirement for members who refuse to participate
  • Cost reimbursement requirement for all tests

Impact Analysis

Who is affected:

  • All Members of the House of Representatives (including Delegates and Resident Commissioners)
  • All Senators

Potential benefits:

  • Increased accountability for elected officials
  • Transparency in Congressional substance use
  • Equal treatment with other federal employees who undergo drug testing

Potential concerns:

  • Privacy considerations for elected officials
  • Constitutional questions about separation of powers
  • Cost and administrative burden

Funding & Implementation

Funding:

  • No direct appropriations mentioned
  • Costs to be reimbursed by individual members

Implementation:

  • Overseen by Committee on House Administration and Senate Committee on Rules and Administration
  • Requires development of specific rules and regulations
  • Ethics Committees responsible for enforcement and disclosure

Responsible entities:

  • House Committee on Ethics
  • Senate Select Committee on Ethics
  • Medical review officers (contracted)

Political Context

Type of legislation:

  • Concurrent resolution (requires passage by both chambers but not presidential signature)
  • Administrative/procedural in nature

Potential areas of debate:

  • Privacy rights vs. public accountability
  • Constitutional separation of powers
  • Administrative burden and cost effectiveness
  • Enforcement mechanisms
  • Equal treatment with other federal employees

Notable aspects:

  • Introduces direct accountability measure for elected officials
  • Creates parity between Congress members and other federal employees subject to drug testing
  • Could face resistance due to privacy concerns and implementation challenges
Model: claude-3-5-sonnet-20241022 Input tokens: 1,301 Output tokens: 490

Latest Action

Jun 5, 2025
Referred to the House Committee on House Administration.

Actions (3)

Referred to the House Committee on House Administration.
Type: IntroReferral | Source: House floor actions | Code: H11100
Jun 5, 2025
Submitted in House
Type: IntroReferral | Source: Library of Congress | Code: H11100
Jun 5, 2025
Submitted in House
Type: IntroReferral | Source: Library of Congress | Code: 1025
Jun 5, 2025

Subjects (1)

Congress (Policy Area)

Text Versions (1)

Introduced in House

Jun 5, 2025
PDF ↗ XML ↗

Full Bill Text

Length: 4,357 characters Version: Introduced in House Version Date: Jun 5, 2025 Last Updated: Nov 13, 2025 6:39 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Con. Res. 35 Introduced in House

(IH) ]

<DOC>

119th CONGRESS
1st Session
H. CON. RES. 35

Requiring Members of the House of Representatives and the Senate to
participate in random drug testing.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

June 5, 2025

Mr. Higgins of Louisiana submitted the following concurrent resolution;
which was referred to the Committee on House Administration

_______________________________________________________________________

CONCURRENT RESOLUTION

Requiring Members of the House of Representatives and the Senate to
participate in random drug testing.

Resolved by the House of Representatives (the Senate concurring),
SECTION 1.

This concurrent resolution may be cited as the ``Exposing
Congressional Drug Abuse Act''.
SEC. 2.
AND THE SENATE.

(a) In General.--Each Member of the House of Representatives and
the Senate shall participate in accordance with this concurrent
resolution in a program for testing for illegal use of controlled
substances.

(b) Features.--The program under this concurrent resolution shall
include the following features:

(1) Each Member of the House of Representatives and the
Senate shall be subject to a random drug test once per term of
such Member.

(2) Each confirmed positive result under the program shall
be provided as follows:
(A) To the Member involved.
(B) In the case of a Member of the House of
Representatives, to the Committee on Ethics of the
House of Representatives for such review as may be
necessary under the Rules of the House of
Representatives.
(C) In the case of a Member of the Senate, to the
Select Committee on Ethics of the Senate for such
review as may be necessary under the Standing Rules of
the Senate.

(3) The Committee on Ethics of the House of
Representatives, with respect to a Member of the House, and the
Select Committee on Ethics of the Senate, with respect to a
Member of the Senate, shall publicly disclose the identity of
each Member who refuses to participate in the program and take
other action against each such Member as appropriate.

(4) Each Member of the House of Representatives and the
Senate shall reimburse the House of Representatives or the
Senate for the cost of the random drug test of such Member
under the program.
(c) Regulations.--The Committee on House Administration of the
House of Representatives and the Committee on Rules and Administration
of the Senate shall each issue such rules and regulations as may be
necessary to carry out this concurrent resolution.
(d) === Definitions. ===
-In this concurrent resolution:

(1) Confirmed positive result.--The term ``confirmed
positive result''--
(A) means a random drug test--
(i) which has initially tested as positive
for the presence of an illegal controlled
substance;
(ii) for which the initially positive test
has been confirmed by a second test using a
different chemical process than the process
used for the initial test; and
(iii) which has been reviewed and certified
as positive by a medical review officer with
whom the House of Representatives or the Senate
has entered into a contract to perform such
reviews; and
(B) does not include a drug test which shows only
the presence of legal, over-the-counter drugs and drugs
that have been legally prescribed for the individual
involved.

(2) Controlled substance.--The term ``controlled
substance'' has the meaning given the term in
section 102 of the Controlled Substances Act (21 U.
the Controlled Substances Act (21 U.S.C. 802).

(3) Member.--The term ``Member'', with respect to the House
of Representatives, includes a Delegate or Resident
Commissioner to the Congress.

(4) Random drug test.--The term ``random drug test'' means
a test conducted for the purpose of detecting the illegal use
of a controlled substance which is conducted--
(A) on a periodic basis;
(B) without advance notice; and
(C) without individualized suspicion.
<all>
View original source ↗
Back to Bills View on Congress.gov